H.C. Wainwright raised the firm’s price target on LifeMD (LFMD) to $10 from $9 and keeps a Buy rating on the shares. The company reported a Q4 beat and its 2026 revenue is expected to grow 13%-19%, the analyst tells investors in a research note.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
